Table 2.
TRPM7methylation in breast cancer: univariate and multivariate models with clinicopathological characteristics
| Characteristics | Univariate | Multivariate | ||
|---|---|---|---|---|
| ORa (95% CI) | P | ORa (95% CI) | P | |
| Ageb | 1.04 (0.84–1.28) | 0.75 | / | / |
| WHO gradec | 0.66 (0.37–1.18) | 0.16 | / | / |
| Molecular subtyped | 1.27 (1.00–1.63) | 0.05 | 1.34 (0.94–1.90) | 0.10 |
| LNMe | 0.09 (0.04–0.22) | 0.001 | 0.09 (0.03–0.27) | 0.001 |
| ER | 1.43 (0.81–2.50) | 0.21 | ||
| PR | 1.33 (0.77–2.29) | 0.30 | ||
| Her2 | 0.61 (0.31–1.20) | 0.15 | ||
| Endocrine therapy | 1.43 (0.81–2.50) | 0.21 | 1.45 (0.76–2.76) | 0.26 |
| Radiotherapy | 0.37 (0.21–0.64) | 0.001 | 0.94 (0.36–2.44) | 0.90 |
| Chemotherapy | 0.56 (0.26–1.20) | 0.14 | 0.09 (0.31–1.97) | 0.61 |
| Relapse | 0.63 (0.29–1.38) | 0.25 | 3.25 (0.49–21.58) | 0.22 |
| Survival statusf | 0.49 (0.23–1.05) | 0.06 | 0.20 (0.03–1.21) | 0.07 |
aOR: odds ratio with 95% confidence interval; bAge (per 10 years); cWHO grade (I, II, III and IV); dMolecular subtype (Luminal A, Luminal B, Her2 positive and Basal like); eLymph node metastasis; fSurvival status (alive vs. dead)